Akoya Biosciences, Inc. AKYA
Set alert
1.29 0.00 0.00%
At close · Jul 8
1.29 Day range 1.29
0.93 52-week range 3.42
- Open
- 1.29
- Prev close
- 1.29
- Mkt cap
- 64.44M
- Vol
- 715.25K
- Avg vol
- 444.06K
- EPS
- -0.97
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.29
- High
- 1.29
- Forward P/E
- -4.38
- Beta
- 1.35
- Short ratio
- 13.43
- Inst. own
- 70.19%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 5, 2024
- 50-d avg
- 2.63
- 200-d avg
- 2.91
- 1y target
- 3.50
Analyst view
Price target (mean) 3.50 +171.3% upside
Now 1.29
- Target (low)
- 3.00
- Target (mean)
- 3.50
- Target (high)
- 5.00
Ratings (0m) 8 3 buy · 5 hold · 0 sell
- Strong buy1
- Buy2
- Hold5
- Sell0
- Strong sell0
Recommendation trend
- This month 8
- 1 month ago 9
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.16248 | -0.19 – -0.12238 | -0.22 | +26.2% | 21.47M | -18.9% | 5 |
| Next quarter | -0.2075 | -0.22 – -0.20 | -0.34705 | +40.2% | 19.98M | +8.9% | 4 |
| Current year | -1.07 | -1.15 – -0.91453 | -1.43 | +25.4% | 81.91M | -15.2% | 4 |
| Next year | -0.62388 | -0.71 – -0.44 | -1.07 | +41.5% | 91.58M | +11.8% | 5 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 19, 2024 | Piper Sandler | Reiterated | Overweight | Overweight |
| Nov 15, 2024 | Craig-Hallum | Downgrade | Buy | Hold |
| Nov 15, 2024 | Canaccord Genuity | Maintained | Buy | Buy |
| Aug 13, 2024 | Piper Sandler | Maintained | Overweight | Overweight |
| Aug 6, 2024 | Morgan Stanley | Downgrade | Overweight | Equal-Weight |
| Aug 6, 2024 | BTIG | Downgrade | Buy | Neutral |
| Aug 6, 2024 | Craig-Hallum | Maintained | Buy | Buy |
| Aug 6, 2024 | JP Morgan | Downgrade | Overweight | Neutral |
| Jun 3, 2024 | Morgan Stanley | Maintained | Overweight | Overweight |
| May 14, 2024 | Canaccord Genuity | Maintained | Buy | Buy |
| May 14, 2024 | BTIG | Maintained | Buy | Buy |
| Mar 6, 2024 | JP Morgan | Maintained | Overweight | Overweight |
| Mar 5, 2024 | UBS | Maintained | Buy | Buy |
| Mar 5, 2024 | Canaccord Genuity | Reiterated | Buy | Buy |
| Dec 14, 2023 | Guggenheim | Initiated | — | Neutral |
| Nov 13, 2023 | Piper Sandler | Maintained | Overweight | Overweight |
| Nov 13, 2023 | Stephens & Co. | Maintained | Overweight | Overweight |
| Oct 24, 2023 | Morgan Stanley | Maintained | Overweight | Overweight |
| Oct 16, 2023 | Piper Sandler | Maintained | Overweight | Overweight |
| Oct 12, 2023 | UBS | Maintained | Buy | Buy |
| Aug 8, 2023 | Morgan Stanley | Maintained | Overweight | Overweight |
| Aug 8, 2023 | Stephens & Co. | Reiterated | Overweight | Overweight |
| May 10, 2023 | Morgan Stanley | Maintained | — | Overweight |
| Mar 21, 2023 | Stephens & Co. | Reiterated | — | Overweight |
| Mar 8, 2023 | Morgan Stanley | Maintained | — | Overweight |
| Nov 3, 2022 | Capital One | Initiated | — | Overweight |
| Oct 6, 2022 | Stephens & Co. | Initiated | — | Overweight |
| Aug 17, 2022 | Piper Sandler | Maintained | — | Overweight |
| Jun 22, 2022 | BTIG | Initiated | — | Buy |
| May 16, 2022 | Piper Sandler | Maintained | — | Overweight |